Figure 4

_VEGF PADS pharmacokinetics and biodistribution. a. Fluorescently labeled free VEGF or _VEGFPADS were administered by IV injection to C57/Bl6 mice. Plasma levels were determined by direct fluorescence quantitation and fit to a two-compartment pharmacokinetic model. b. _VEGFPADS had a slower plasma clearance rate than free VEGF, as was evidenced by lower levels in the urine at the end of the experiment c. Data represent the mean ± sd of four mice per group. *p = 0.03, Student’s t-test. d. ELP fusion significantly altered the biodistribution of VEGF, increasing its levels in the spleen and liver and reducing its levels in the kidney. *p <0.05, two-way ANOVA with post-hoc Bonferroni multiple comparison.